BOSTON — eClinical Solutions said it closed 2025 with significant growth and industry recognition while unveiling new innovations for 2026 aimed at accelerating clinical trials and improving efficiency across the clinical research lifecycle.
The company said it added more than 20 net new customers last year, expanding its biopharma and contract research organization client base to include 18 of the world’s top 50 pharmaceutical companies. eClinical Solutions said its progress reflects increasing demand for an AI-first, risk-based approach to clinical development.
During 2025, the company continued evolving its elluminate platform into a clinical data intelligence system designed to improve trial efficiency. This included the launch of elluminate agents, which use shared data context, defined workflows, and agentic, assistive, and task-oriented AI supported by governance guardrails and policies. The company also introduced a digitized Integrated Data Review Plan, which it said makes eClinical Solutions the first to centralize digital data review within a single platform.
The company also announced an industry collaboration with ZS, combining eClinical Solutions’ risk-based quality management technology with ZS’ consulting and custom solution expertise to create an integrated quality risk management experience for clinical trial sponsors.
Additional 2025 highlights included recognition in an Everest Group report focused on risk-based quality management technology providers, along with workplace honors such as the 2025 Top Workplace USA Award for Remote Work and the 2025 Top Workplaces Culture Excellence Award for Work-Life Flexibility, marking the fourth consecutive year of recognition. The Society for Clinical Data Management also awarded eClinical Solutions its Innovation Award for Advancements in Health Insight Generation and elected Dawn Kaminski, vice president of business development operations, as executive secretary of the organization’s board for 2026.
Building on that momentum, eClinical Solutions said it has rolled out new enhancements to the elluminate platform in 2026 to help sponsors comply with updated ICH E6 R(3) guidelines and expand agentic AI capabilities. The updates include automated, protocol-aware data review tools, expanded end-to-end traceability for risk-based quality management, faster and more consistent RBQM setup at the study level, guided centralized monitoring workflows, and agentic automation for SDTM mapping and dataset generation using Python, R, or SAS with full traceability.
“Insight from clients and partners at ENGAGE 2025 and the data from our 2025 Industry Outlook Survey reaffirmed our conviction of creating a strong data intelligence foundation through the elluminate platform that elicits scalable innovation, from embedding intelligence to risk-based approaches,” said Raj Indupuri, CEO and co-founder of eClinical Solutions. “As we look at our next phase of growth, we’re hyper-focused on driving return on investment for our clients and leaning into agentic AI in 2026, for the next era of clinical trial automation.”
